
This retrospective cohort study analyzed 1911 adults with a BMI ≥30 kg/m2 who initiated antiobesity medication (AOM) between 2015 and 2022. Results revealed varying persistence rates at 3, 6, and 12 months, with semaglutide showing the highest 1-year persistence (40%). Semaglutide was associated with increased odds of 1-year persistence, while naltrexone-bupropion had lower odds compared to phentermine-topiramate. Among those persistent at 6 months, a 1% increase in weight loss was linked to 6% higher odds of year-long persistence.
Like
Save
Share